Level C· Early human research exploring benefitsProspective StudyPubMedOpen access

Functionally enhanced placenta-derived mesenchymal stem cells inhibit adipogenesis in orbital fibroblasts with Graves' ophthalmopathy.

Kim JY., Park S., Lee HJ., Lew H., Kim GJ.

Prospective Study on Immune Modulation, Autoimmune Research, published in Stem Cell Res Ther (2020) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Stem Cell Res Ther (2020)
Country
England
Reported sample size
—
Source database
PubMed
PMID
33153489
PMCID
PMC7643360
DOI
10.1186/s13287-020-01982-3
Citations
21

Abstract (original English)

Background Placenta-derived mesenchymal stem cells (PD-MSCs) have unique immunomodulatory properties. Phosphatase of regenerating liver-1 (PRL-1) regulates the self-renewal ability of stem cells and promotes proliferation. Graves' ophthalmopathy (GO) is an autoimmune inflammatory disease of the orbit and is characterized by increased orbital levels of adipose tissue. Here, we evaluated the therapeutic mechanism for regulation of adipogenesis by PRL-1-overexpressing PD-MSCs (PD-MSCs PRL-1 , PRL-1+) in orbital fibroblast (OF) with GO patients. Methods PD-MSCs isolated from human placenta were transfected with the PRL-1 gene using nonviral transfection method. Primary OFs were isolated from orbital adipose tissue specimens from GO patients. After maturation as adipogenic differentiation, normal and GO-derived OFs were cocultured with naïve and PD-MSCs PRL-1 . We analyzed the protein levels of adipogenesis markers and their signaling pathways in OFs from GO patients. Results The characteristics of PD-MSCs PRL-1 were similar to those of naïve cells. OFs from GO patients induced adipocyte differentiation and had significantly decreased a lipid accumulation after coculture with PD-MSCs PRL-1 compared to naïve cells. The mRNA and protein expression of adipogenic markers was decreased in PD-MSCs PRL-1 . Insulin-like growth factor-binding proteins (IGFBPs) secreting PD-MSCs PRL-1 downreg

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AdipogenesisCells, CulturedFemaleFibroblastsGraves OphthalmopathyHumansMesenchymal Stem CellsOrbitPhosphatidylinositol 3-KinasesPlacenta

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research